GHIT Fund Global Health Innovative Technology Fund

Investments

Clinical Candidates

Over ten GHIT development partnerships have conducted clinical programs worldwide.
Please see each program to know more details.

    • SILVAMPTM TBLAM

      1. Disease: Tuberculosis
      2. Intervention: Diagnostics
      3. Development Stage: Field Validation
      4. Country: South Africa, Malawi, Zambia, Tanzania, Uganda, Vietnam, Thailand
      Details
    • Photo credit: Biopromic AB

      BP-AK urine LAM test

      1. Disease: Tuberculosis
      2. Intervention: Diagnostics
      3. Development Stage: Product Development
      4. Country: South Africa, Uganda
      Details

    • Lung Flute ECO

      1. Disease: Tuberculosis
      2. Intervention: Diagnostics
      3. Development Stage: Field Validation
      4. Country: Cameroon
      Details

    • SJ733

      1. Disease: Malaria
      2. Intervention: Drug
      3. Development Stage: Phase IIa
      4. Country: Peru
      Details

    • BK-SE36/CpG & NPC-SE36/CpG

      1. Disease: Malaria
      2. Intervention: Vaccine
      3. Development Stage: Phase IIb
      4. Country: Burkina Faso
      Details

    • SMAART-1

      1. Disease: Malaria
      2. Intervention: Diagnostics
      3. Development Stage: Product Development
      4. Country: Democratic Republic of Congo
      Details

    • Arpraziquantel

      1. Disease: Schistosomiasis
      2. Intervention: Pediatric Drug
      3. Development Stage: Phase III, Registration, Access
      4. Country: Côte d’Ivoire, Kenya
      Details

    • Fosravuconazole

      1. Disease: Mycetoma
      2. Intervention: Drug
      3. Development Stage: Phase II
      4. Country: Sudan
      Details
    • Photo credit: Vinicius Berger-DNDi

      CpG-D35

      1. Disease: Cutaneous leishmaniasis
      2. Intervention: Drug
      3. Development Stage: Phase I
      4. Country: UK, Columbia
      Details
    • Photo credit: Kate Dodd

      AWZ1066S

      1. Disease: Lymphatic filariasis / Onchocerciasis
      2. Intervention: Drug
      3. Development Stage: Phase I
      4. Country: UK
      Details
    • Photo credit: FIND

      BU-MYCOLAC

      1. Disease: Buruli ulcer
      2. Intervention: Diagnostics
      3. Development Stage: Product Development
      4. Country: Cameroon, Côte d'Ivoire
      Details
    • Photo credit: CONICET-INGEBI

      Trypanosoma cruzi-LAMP

      1. Disease: Chagas disease
      2. Intervention: Diagnostics
      3. Development Stage: Product Development
      4. Country: Argentina, Bolivia, Paraguay
      Details

    • SCH CAA RDT

      1. Disease: Schistosomiasis
      2. Intervention: Diagnostics
      3. Development Stage: Product Development
      4. Country: Kenya, Philippines
      Details